Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Non-randomized, Single Arm, Translational Study of Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment

NCT04511455 is registered in ClinicalTrials.gov with Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest as lead sponsor.

NCT NCT04511455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04511455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Non-randomized, Single Arm, Translational Study of Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment
Lead sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase
Phase 2
Overall status
Completed
Start date
December 8, 2020
Completion date
December 31, 2024
Enrollment
22 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma non-resectable, metastatic hepatocellular carcinoma